Targeted drug and gene delivery systems for lung cancer therapy

Clinical Cancer Research

Volumn 15, Issue 23, 2009, Pages 7299-7308

  Sundaram, Sneha ^a,b   Trivedi, Ruchit ^b   Durairaj, Chandrasekar ^b   Ramesh, Rajagopal ^c   Ambati, Balamurali K ^d   Kompella, Uday B ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTISENSE OLIGONUCLEOTIDE; ARGINYLGLYCYLASPARTIC ACID; DESLORELIN; DOCETAXEL; GONADORELIN RECEPTOR; NANOPARTICLE; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER MODEL; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENTIATION; DRUG SCREENING; DRUG TARGETING; GENE DELIVERY SYSTEM; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; MALE; MOUSE; NANOENCAPSULATION; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; TUMOR XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; GENE TRANSFER TECHNIQUES; HUMANS; LUNG NEOPLASMS; MEDICAL ONCOLOGY; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; OLIGONUCLEOTIDES, ANTISENSE; OLIGOPEPTIDES; TRIPTORELIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 73149103429     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1745     Document Type: Article

References (35)

1. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008;83:584-94.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CACancer J Clin 2008;58:71-96.
3. Cancer Facts and Figures. American Cancer Society 2008.
4. Stinchcombe TE, Socinski MA. Considerations for second-line therapy of non-small cell lung cancer. Oncologist 2008;13 Suppl 1:28-36.
5. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004;22:330-53.
6. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-103.
7. Vaishampayan U, Hussain M. Update in systemic therapy of prostate cancer: improvement in quality and duration of life. Expert Rev Anticancer Ther 2008;8:269-81.
8. Coy DH, Coy EJ, Vilchez-Martinez JA, de la Cruz A, Arimura A, Schally AV. Suppression of gonadotropin release and ovulation in animals by inhibitory analogs of luteinizing hormone-releasing hormone. Curr Top Mol Endocrinol 1976;3:339-54.
9. Sundaram S, Bontha S, Kompella UB. Respiratory delivery of deslorelin, a peptide drug. Am Pharm Rev 2004;7:130-9.
10. Tieva A, Stattin P, Wikstrom P, Bergh A, Damber JE. Gonadotropin- releasing hormone receptor expression in the human prostate. Prostate 2001;47:276-84.
11. Koushik K, Bandi N, Sundaram S, Kompella UB. Evidence for LHRH-receptor expression in human airway epithelial (Calu-3) cells and its role in the transport of an LHRH agonist. Pharm Res 2004;21:1034-46.
12. KakarSS, Jennes L.Expression of gonadotropin-releasing hormone and gonadotropin-releasing hormone receptor mRNAs in various nonreproductive human tissues. Cancer Lett 1995;98:57-62.
13. Sundaram S, Durairaj C, Kadam R, Kompella UB. Luteinizing hormone-releasing hormone receptor-targeted deslorelin-docetaxel conjugate enhances efficacy of docetaxel in prostate cancer therapy. Mol Cancer Ther 2009;8:1655-65.
14. Harmey JH, Bouchier-Hayes D. Vascular endothelial growth factor (VEGF), a survival factor for tumour cells: implications for anti-angiogenic therapy. BioEssays 2002;24:280-3.
15. Fontanini G, Vignati S, Boldrini L, et al. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res 1997;3:861-5.
16. Sweeney CJ, Miller KD, Sissons SE, et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001;61:3369-72.
17. Lee CG, Heijn M, di Tomaso E, et al. Antivascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 2000;60:5565-70.
18. Sandler A, Gray R, Perry MC, et al. Paclitaxelcarboplatin alone or with bevacizumab for nonsmall-cell lung cancer. N Engl J Med 2006;355:2542-50.
19. Sandler AB. Advanced non-small-cell lung cancer: new data, therapy choices, and challenging decisions. Oncology (Huntingt) 2006;20:626-8.
20. Singh N, Amin S, Richter E, et al. Flt-1 intraceptors inhibit hypoxia-induced VEGF expression in vitro and corneal neovascularization in vivo. Invest Ophthalmol Vis Sci 2005;46:1647-52.
21. Yla-Herttuala S. Vascular gene transfer. Curr Opin Lipidol 1997;8:72-6.
22. Kumar S, Li C. Targeting of vasculature in cancer and other angiogenic diseases. Trends Immunol 2001;22:129.
23. Vogel BE, Lee SJ, Hildebrand A, et al. A novel integrin specificity exemplified by binding of the α v β 5 integrin to the basic domain of the HIV Tat protein and vitronectin. J Cell Biol 1993;121:461-8.
24. Sundaram S, Roy SK, Kompella UB. Differential expression of LHRH-receptor in bovine nasal tissue and its role in deslorelin delivery. Peptides 2009;30:351-8.
25. Seong JY, Kang SS, Kam K, et al. Differential regulation of gonadotropin-releasing hormone (GnRH) receptor expression in the posterior mediobasal hypothalamus by steroid hormones: implication of GnRH neuronal activity. Brain Res Mol Brain Res 1998;53:226-35.
26. Sundaram S, Roy SK, Ambati BK, Kompella UB. Surface-functionalized nanoparticles for targeted gene delivery across nasal respiratory epithelium. FASEB J 2009.
27. Kompella UB, SundaramS, Raghava S, Escobar ER. Luteinizing hormone-releasing hormone agonist and transferrin functionalizations enhance nanoparticle delivery in a novel bovine ex vivo eye model. Mol Vis 2006;12:1185-98.
28. Koushik KN, Kompella UB. Transport of deslorelin, an LHRH agonist, is vectorial and exhibits regional variation in excised bovine nasal tissue. J Pharm Pharmacol 2004;56:861-8.
29. Raghava S, Goel G, Kompella UB. Ophthalmic Applications of Nanotechnology. New York: Humana Press; 2008.
30. Inoue S, Hartman A, Branch CD, et al. mda-7 in combination with bevacizumab treatment produces a synergistic and complete inhibitory effect on lung tumor xenograft.Mol Ther 2007;15:287-94.
31. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995;1:149-53.
32. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996;2:689-92.
33. Avramis IA, Kwock R, Avramis VI. Taxotere and vincristine inhibit the secretion of the angiogenesis inducing vascular endothelial growth factor (VEGF) by wild-type and drug-resistant human leukemia T-cell lines. Anticancer Res 2001;21:2281-6.
34. Guo XL, Lin GJ, Zhao H, et al. Inhibitory effects of docetaxel on expression of VEGF, bFGF and MMPs of LS174T cell. World J Gastroenterol 2003;9:1995-8.
35. Niwa H, Wentzel AL, Li M, Gooding WE, Lui VW, Grandis JR. Antitumor effects of epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck. Clin Cancer Res 2003;9:5028-35.